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TH1 cells are critical for the control of many   
intracellular pathogens because cell contact– 
dependent signals and the secretion of cytokines, 
including IFN- and TNF, activate infected cells 
to produce antimicrobial effector molecules.   
After resolution and clearance of infection, effec-
tor T cells need to be deleted to prevent exces-
sive  tissue  inflammation  and  development  of 
immunopathology. Tim3, a member of the re-
cently discovered T cell Ig and mucin domain– 
containing molecule (Tim) superfamily, is a 
negative regulator of TH1 immunity (Monney 
et al., 2002). As such, Tim3 acts to suppress auto-
immunity  in  the  mouse  EAE  and  arthritis 
models (Sabatos et al., 2003; Sánchez-Fueyo 
et al., 2003; Zhu et al., 2005; Seki et al., 2008). 
The human Tim3 orthologue appears to func-
tion similarly in people (Yang et al., 2008).
The only known ligand of Tim3 is galectin-9 
(Gal9),  a  ubiquitously  expressed  soluble   
-galactoside–binding protein (Zhu et al., 2005; 
Cao et al., 2007). Both IFN- and IL-1 induce 
Gal9,  which  enhances Tim3–Gal9  interaction 
during TH1-type immunity and tissue inflamma-
tion (Yoshida et al., 2001; Imaizumi et al., 2002). 
Binding of Gal9 to Tim3 transduces a signal into 
T cell that triggers apoptosis, resulting in clonal 
contraction of effector TH1 cells (Kashio et al., 
2003; Zhu et al., 2005). Similarly, Tim3 expres-
sion by effector CD4+ and CD8+ T cells during 
HIV and hepatitis C virus (HCV) infection is 
associated with T cell dysfunction and correlates 
with  disease  progression  (Jones  et  al.,  2008; 
Golden-Mason et al., 2009). Under these condi-
tions, Tim3–Gal9 interaction may lead to in-
appropriate exhaustion or apoptosis of Tim3+ 
effector T cells (Kashio et al., 2003). Although 
such a response may be an adaptation to chronic 
infection or inflammation that limits the devel-
opment of immunopathology, disrupting T cell 
responses against pathogenic microbes may be 
detrimental to the host.
The  ability  of  pathogenic  Mycobacterium   
tuberculosis (Mtb) to adapt to the hostile intracellu-
lar environment of the macrophage has been in-
strumental to its success as a pathogen. Host re-
sistance  against  Mtb  relies  on  TH1-mediated 
immunity (Flynn and Chan, 2001). Importantly, 
effector TH1  cells  are  understood  to  mediate 
protective immunity by depriving the bacterium 
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T cell immunoglobulin and mucin domain 3 (Tim3) is a negative regulatory molecule that 
inhibits effector TH1-type responses. Such inhibitory signals prevent unintended tissue 
inflammation, but can be detrimental if they lead to premature T cell exhaustion. Although 
the role of Tim3 in autoimmunity has been extensively studied, whether Tim3 regulates 
antimicrobial immunity has not been explored. Here, we show that Tim3 expressed on  
TH1 cells interacts with its ligand, galectin-9 (Gal9), which is expressed by Mycobacterium 
tuberculosis–infected macrophages to restrict intracellular bacterial growth. Tim3–Gal9 
interaction leads to macrophage activation and stimulates bactericidal activity by inducing 
caspase-1–dependent IL-1 secretion. We propose that the TH1 cell surface molecule Tim3 
has evolved to inhibit growth of intracellular pathogens via its ligand Gal9, which in turn 
inhibits expansion of effector TH1 cells to prevent further tissue inflammation.
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months after the publication date (see http://www.rupress.org/terms). After six 
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mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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of its intracellular niche. The production of IFN- and TNF by 
Mtb-specific TH1 cells serves to activate infected macrophages, 
which induces intracellular mediators such as nitric oxide (NO) 
and promotes changes in intracellular physiology including 
phagolysosome fusion (Cooper et al., 1993; Flynn et al., 1993; 
MacMicking et al., 2003; Harris et al., 2008). Although IFN- 
is necessary for optimum antimycobacterial immunity, studies 
in humans indicate that IFN- levels do not necessarily predict 
disease progression (Zhang et al., 1995; Bhattacharyya et al., 
1999; Flynn, 1999).
Because control of Mtb requires TH1 cells, we hypothe-
sized that Tim3 would play a critical role in modulating host 
resistance to tuberculosis. Although Tim3 expression on   
T cells negatively regulates their expansion, how Tim3–Gal9 
binding affects the Gal9-expressing APCs has not previously 
been addressed. We show that Mtb-infected macrophages ex-
press high levels of Gal9 and that Tim3 binding to its ligand 
Gal9 expressed by Mtb-infected macrophages activates innate 
pathways and inhibit intracellular bacterial replication. These 
data support a model in which Tim3–Gal9 interact as a bidi-
rectional regulatory circuit that activates innate immune cells 
to clear intracellular pathogens, which in turn further up- 
regulate Tim3 ligand and Gal9 and promote termination of 
TH1 responses.
RESULTS
Tim3 and Gal9 expression after low-dose aerosol Mtb 
infection in mice
To determine the potential of Tim3 to modulate immunity to 
Mtb, its expression on T cells from uninfected and Mtb- 
infected mice was analyzed. In uninfected mice, Tim3 is 
expressed by only 1–2% of lung T cells. In contrast, after low-
dose aerosol Mtb infection, the percentage of pulmonary 
CD4+ and CD8+ T cells that express Tim3 gradually increases 
(Fig. 1 A). During the chronic phase of infection, nearly 40% 
of all pulmonary CD8+ T cells and 20% of all pulmonary 
CD4+ T cells express Tim3 (Fig. 1 B). Similarly the frequency 
of splenic CD4+ and CD8+ T cells that express Tim3 increases 
after Mtb infection (unpublished data). The Tim3+ CD4+ and 
CD8+ T cells have an effector phenotype and secrete higher 
levels of TH1 cytokines, such as IFN- and TNF, than Tim3 
T cells (unpublished data). In addition, we determined the 
expression of the Tim3 ligand, Gal9, by myeloid cells in the 
lung. To discriminate alveolar macrophages from other cell 
subsets, we used a cocktail of antibodies recognizing F4/80, 
CD11b, and CD11c. Alveolar macrophages are F4/80+ CD11c+ 
CD11blow in uninfected mice and can become F4/80+ CD11c+ 
CD11bhi after infection. We measured intracellular levels of 
Gal9 in CD11c+ CD11bhi/ cells in the lungs of uninfected 
and Mtb-infected mice and found high levels of Gal9 in both 
of these myeloid cell subsets (Fig. 1 C). The other myeloid 
cell subsets in the lungs of infected mice also expressed Gal9 
(Fig. S1 A). The accumulation of Tim3+ T cells in the lungs 
after Mtb infection and the pulmonary expression of Gal9 
supports a function for Tim3 and Gal9 during host immunity 
to infection.
Figure 1.  Tim3 and Gal9 expression in the lungs of uninfected and 
Mtb-infected mice. (A) Total lung cells were prepared from uninfected 
or Mtb-infected (8 and 24 wk after aerosol infection) C57BL/6 mice. Lym-
phocytes were gated based on size and on CD8+ or CD4+ staining, and the 
expression of Tim3 by CD4+ or CD8+ T cells is shown in the histograms 
(thick line). Shaded histograms represent isotype control. Representative 
FACS plots from 10 independent experiments performed 4–24 wk after 
infection is shown for a single animal at 8 and 24 wk after Mtb infection 
is shown. (B) The percentage of CD4+ and CD8+ T cells that express Tim3 is 
represented in graphs. Data represent 3–12 determinations from 10 inde-
pendent experiments, done 4–24 wk after infection (some of the symbols 
are superimposed). The horizontal bar represents the median. (C) Myeloid 
cell subsets in the lung were identified based on CD11c and CD11b stain-
ing, and the expression of intracellular Gal9 (thick line) by CD11c+ (R1) or 
CD11b+ CD11c+ (R2) cells were determined. Shaded histograms represent 
isotype control. Representative histograms are shown for a cohort of mice 
(n = 4–5 for infected mice; n = 3 for naive mice). Data represent three 
independent experiments performed 4–40 wk after infection. Numbers 
indicate the percentage of cells in each gate, and mean values ± SD are 
shown in the top right corner of each plot.JEM VOL. 207, October 25, 2010 
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of the bacterial burden by Tim3-Ig was sustained in the lung 
(Fig. 2 C) but not the spleen (not depicted) 3 wk after infec-
tion. This suggests that the antimicrobial effect of Tim3-Ig 
was independent of acquired immunity. Furthermore, these 
data raised the possibility that Tim3-Ig was acting as an ago-
nist and that its binding to host macrophage-activated innate 
antimicrobial pathways.
Tim3–Gal9 interaction leads to macrophage activation  
and stimulation of innate immunity
We hypothesized that the ability of Tim3-Ig to limit Mtb 
growth in the lungs of infected mice was caused by its direct 
interaction with infected macrophages. To test this hypothesis, 
Mtb-infected macrophages were treated with purified Tim3-Ig 
fusion protein or human IgG in vitro. The CFU recovered 
from Mtb-infected macrophages on day 4 was lower than the 
day 1 inoculum at all concentrations of Tim3-Ig tested (Fig. 3 A). 
At a dose of 30 µg/ml, 68% of the day 1 bacteria are killed 
(P < 0.05, one-way analysis of variance [ANOVA]). Tim3-Ig 
treatment of infected WT and Tim3/ macrophages induced 
similar control of bacterial replication, which indicated that Tim3 
expression by the macrophages was not necessary (Fig. 3 B). 
These results demonstrate that Tim3-Ig acts as an agonist and 
induces intracellular Mtb killing in the absence of T cells.
The only known ligand of Tim3 is Gal9 (Zhu et al., 2005; 
Cao et al., 2007). Gal9 is expressed by peritoneal macrophages, 
and Mtb infection induces its expression in a manner that is 
synergistic with IFN- (Fig. S1, B and C). Because Gal9 is a 
-galactoside binding S-type lectin that recognizes Tim3 via 
carbohydrates on the IgV domain, the Tim3–Gal9 interaction 
can be competitively blocked using lactose (Zhu et al., 2005). 
High concentrations of lactose inhibit the antimicrobial activity 
of Tim3-Ig, indicating that Tim3 interaction with Gal9 is re-
quired to induce macrophage antimicrobial activity (Fig. 3 C). 
To confirm these results, WT and Gal9/ macrophages were 
infected with Mtb and treated with Tim3-Ig. Tim3-Ig treatment 
of Mtb-infected Gal9/ macrophages did not affect Mtb 
growth, confirming that Tim3–Gal9 interaction is required to 
stimulate macrophage bactericidal activity (Fig. 3 D).
We next hypothesized that Tim3+ T cells could recapitu-
late the antimicrobial activity of Tim3-Ig by binding to Gal9 
on infected macrophages, which would activate bactericidal 
pathways to kill Mtb. Because T cells from Mtb-infected mice 
have multiple effector functions that also control bacterial 
growth, we wished to determine whether Tim3–Gal9 limits 
bacterial growth in the absence of other T cell functions. 
Therefore, we used Tim3 transgenic (Tim3tg) mice, which 
were generated on the C57BL/6J background and express 
the Tim3 transgene (the BALB/c allele) under the control of 
the hCD2 promoter. Although 1–3% of splenic T cells from 
WT C57BL/6J mice express Tim3, Tim3 is constitutively ex-
pressed by 40–60% of T cells from Tim3tg mice (Fig. S2). 
Splenocytes from uninfected WT mice suppress intracellular 
Mtb growth in primary macrophages by 36% by day 4 (Fig. 3 E; 
Sada-Ovalle et al., 2008). In contrast, Tim3tg splenocytes sup-
press intracellular Mtb growth by 74% compared with day 4, 
Tim3-Ig reduces the mycobacterial burden in vivo
Accumulating evidence indicates that T cells expressing Tim3 
during chronic viral infection are dysfunctional and Tim3 
blockade can reverse exhaustion and restore normal effector 
function (Jones et al., 2008; Golden-Mason et al., 2009). The 
accumulation of Tim3+ T cells in the lungs after Mtb infec-
tion raised the possibility that Tim3 contributes to T cell dys-
function.  To  determine  whether  blocking  Tim3  would 
enhance pulmonary immunity to Mtb, mice were infected 
with  low-dose  aerosolized  virulent  Mtb,  and  then  treated 
with fusion protein expressing full-length or soluble forms of 
mouse Tim3 and human Ig Fc tail (flTim3-Ig, sTim3-Ig) or 
control, human Ig- (HuIgG; Sabatos et al., 2003; Zhu et al., 
2005). Mice that received flTim3-Ig had a lower bacterial 
burden in the lung and spleen compared with mice treated 
with HuIgG (Fig. 2 A). To establish that the beneficial effect 
of Tim3-Ig on control of Mtb infection was a consequence 
of blocking Tim3 signaling on T cells, the experiment was 
repeated using RAG/ mice. RAG/ mice were similarly 
infected and treated with sTim3-Ig, flTim3-Ig, or control 
HuIgG. Treatment with either sTim3-Ig or flTim3-Ig led to 
a significant reduction in CFU in both the lung and spleen 
within 2 wk after infection (Fig. 2 B), and improved control 
Figure 2.  Tim3-Ig controls Mtb infection in vivo. WT C57BL/6J (A) 
and RAG/ (B and C) mice were infected by the aerosol route with Mtb. 
The next day, 500 µg of full-length Tim3-Ig (flTim3-Ig), soluble Tim3-Ig 
(sTim3-Ig), or HuIgG (control) was administered. Additional protein was 
administered (100 µg) 5, 8, and 12 d after infection. On days 14 (A and B) 
and 21 (C), mice were sacrificed and CFUs were determined in their lungs 
and spleens. Closed and open symbols represent WT B6 and RAG/ mice, 
respectively. Data are representative of three independent experiments, 
with each experiment having n = 5 mice per group. Each point represents 
an individual mouse. *, P < 0.05; **, P < 0.01; ***, P < 0.001, one-way 
ANOVA compared with HuIgG control for the respective mouse strain.2346 Tim3–Gal9 interaction in tuberculosis | Jayaraman et al.
lungs  and  spleen  compared  with  mice  that  received  Mtb- 
infected WT (Gal9+/+) macrophages 7 and 14 d after infec-
tion (Fig. 3 F). These results show that interaction between 
Tim3 and Gal9 in vivo leads to control of intracellular Mtb.
A soluble factor induced by Tim3–Gal9 interaction leads  
to control of bacterial infection
The best described mechanism that restricts intracellular Mtb 
replication is the induction of inducible NO synthase (iNOS) 
and subsequent NO production, which occurs after the acti-
vation of macrophages by IFN- (Denis, 1991; Flynn et al., 
1993). Other cellular mechanisms that reduce Mtb viability, 
such as autophagy and phagolysosomal fusion mediated by 
LRG-47 family of GTPases, are also dependent on activation 
and 51% compared with the day 1 initial inoculum. Purified 
Tim3+CD4+ T cells were sufficient to mediate control of Mtb 
replication and induce a 64% reduction in CFU compared 
with day 1. Splenocytes from Tim3/ mice were unable to 
restrict intracellular bacterial replication, as well as WT sple-
nocytes (Fig. S3). Thus, Tim3 expression by T cells can induce 
killing of intracellular Mtb.
The antimicrobial effect of Tim3-Ig in Rag/ mice is 
consistent with Gal9 signaling activating innate cells to control 
intracellular pathogens. To show that Tim3 and Gal9 interact 
in vivo, WT and Gal9/ macrophages were infected with 
Mtb in vitro and intravenously transferred into uninfected 
Tim3tg recipients. Mice that received Mtb-infected Gal9/ 
macrophages had a significantly higher bacterial burden in the 
Figure 3.  Tim3–Gal9 interaction stimulates antimycobacterial activity. (A) H37Rv-infected macrophages (MP) were cultured alone or in the pres-
ence of increasing amounts of Tim3-Ig fusion protein or with 30 µg/ml of HuIgG as a control. Data are representative of three independent experiments. 
Error bars indicate mean ± SEM from three to six replicate cultures. (B) Mtb-infected WT or Tim3/ macrophages were cultured alone or in the presence 
of 10 µg/ml of sTim3-Ig or HuIgG (control). (C) Mtb-infected macrophages were cultured alone or treated with 10 µg/ml Tim3-Ig in the presence of in-
creasing amounts of lactose. Data are representative of three independent experiments. Error bars indicate mean ± SEM from three replicate cultures.  
(D) Mtb-infected WT or Gal9/ macrophages were cultured alone or in the presence of 10 µg/ml Tim3-Ig or HuIgG (control). Data are representative of 
three independent experiments. Bars indicate mean ± SEM from three replicate cultures. (E) Mtb-infected macrophages cultured alone or with splenocytes 
from uninfected WT (WT Spl) or Tim3tg (Tg Spl) mice, or with Tim3+CD4+ T cells from uninfected Tim3tg mice. In all experiments (unless otherwise noted), 
day 1 (d1) is the CFU in infected macrophages alone 24 h after infection, before the addition of cells or Tim3-Ig or HuIgG and represents initial inoculum, 
whereas day 4 (d4) is the CFU recovered from macrophages 4 d after infection in the absence of any treatment. Data are representative of 3–11 indepen-
dent experiments. Error bars indicate mean ± SEM from three to six replicate cultures. **, P < 0.01; ***, P < 0.001, one-way ANOVA compared with day 4 
macrophages alone. (F) Pulmonary and splenic bacterial burden 7 and 14 d after intravenous transfer of H37Rv-infected WT or Gal9/ macrophages into 
naive Tim3tg mice. Bacteria in lungs and spleen on day 1 after adoptive transfer were 60 and 1088, respectively. Data are from a single experiment with 
two time points (n = 5 mice per group per time point; error bars represent the SEM). **, P < 0.01; ***, P < 0.001, unpaired two-tailed Student’s t test.JEM VOL. 207, October 25, 2010 
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increased level of MIP-2 and RANTES (Fig. S5). Although 
IL-18 was not included in this analysis, Tim3-Ig treatment of 
Mtb-infected macrophages increases IL-1 and IL-18 tran-
scription (Fig. S6). The appearance of IL-1 in the culture 
supernatants indicates that active caspase-1 is expressed by Mtb-
infected cells treated with Tim3-Ig.
To verify the results of the proteomic blot and to confirm 
whether the secretion of active IL-1 is caspase-1 dependent, 
IL-1 was measured in supernatants from uninfected and Mtb-
infected WT and caspase-1/ macrophages treated with and 
without Tim3-Ig. IL-1 was detected only in supernatants 
from Mtb-infected WT macrophages treated with Tim3-Ig 
(Fig. 5 A). We next addressed whether caspase-1 is required 
for the antimicrobial action mediated by Tim3-Ig. WT and 
caspase-1/ macrophages treated with Tim3-Ig fusion pro-
tein were compared for their ability to suppress mycobacterial 
replication. Both Tim3-Ig and Tim3tg CD4+ T cells sup-
pressed intracellular bacterial growth in WT macrophages. 
However, treatment with Tim3-Ig or co-culture of Tim3tg 
CD4+ T cells with Mtb-infected caspase-1/ macrophages 
had no effect on the intracellular growth of Mtb (Fig. 5 B).   
To confirm these results, infected WT macrophages were 
treated with a caspase-1 inhibitor. Increasing concentrations of 
Z-YVAD-Fmk, but not a control peptide, abrogated Tim3-Ig 
mediated control of Mtb infection (Fig. 5 C). These results 
demonstrate that the secretion of IL-1 and control of Mtb 
replication induced by Tim3-Ig is dependent on macrophage 
caspase-1 activity.
Tim3–Gal9 does not increase death of  
Mtb-infected macrophages
Certain pathogens induce pyroptosis, a form of host cell   
necrosis that is dependent on caspase-1 activity (Bergsbaken 
and Cookson, 2007). Our finding that control of Mtb replica-
tion after Tim3-Ig treatment is associated with caspase-1– 
dependent  IL-1  production  raised  the  possibility  that 
restriction of intracellular growth was mediated by pyroptosis. 
Tim3-Ig treatment did not appear to induce necrosis under 
our in vitro infection conditions, as measured by the lactate 
of  infected  macrophages  with  IFN-  (MacMicking  et  al., 
2003; Gutierrez et al., 2004). We assumed that the action of 
Tim3-Ig was IFN-–independent because there is no source 
of IFN- (such as T cells or NK cells) in our culture system, 
nor do we see induction of IFN- RNA or IFN- secretion 
(unpublished data). To definitively rule out the involvement 
of IFN- and iNOS in Tim3–Gal9–mediated Mtb killing, 
IFN-R/ and iNOS/ macrophages were infected with 
Mtb and treated with Tim3-Ig. Tim3-Ig suppressed the intra-
cellular growth of Mtb in both IFN-R/ and iNOS/ 
macrophages (Fig. 4 A). In addition, iNOS inhibitors did not 
affect killing mediated by Tim3tg splenocytes (Fig. S4). These 
data indicate that Tim3–Gal9 interaction leads to killing of 
Mtb independently of IFN- receptor signaling and iNOS 
production and strongly suggest that Tim3 activates a novel 
antibacterial pathway in Mtb-infected macrophages.
We next considered whether soluble mediators secreted 
after Tim3–Gal9 interaction act in an autocrine manner to 
restrict intracellular mycobacterial growth. To evaluate this 
possibility, supernatants were collected from infected macro-
phages 24 h after infection alone, or after treatment with 
Tim3-Ig or HuIgG. Supernatants from Tim3-Ig–treated in-
fected macrophages induced Mtb killing, indicating that a 
soluble mediator secreted after Tim3–Gal9 interaction was 
sufficient to activate macrophages to reduce intracellular Mtb 
viability (Fig. 4 B).
Mtb killing requires caspase-1 and IL-1
To determine which soluble mediators are produced by   
Mtb-infected macrophages after Tim3–Gal9 interaction, we   
profiled the cytokines in supernatants from Mtb-infected macro-
phages that were treated with or without Tim3-Ig. Under 
our in vitro conditions, uninfected macrophages constitu-
tively produce significant amounts of IP10, TIMP-1, KC, JE, 
IL-1R antagonist (IL-1RA), and MIP-2 (Fig. S5). A similar 
pattern of cytokines and chemokines is detected after Tim3-Ig 
treatment of uninfected macrophages. In contrast, Tim3-Ig 
treatment of Mtb-infected macrophages stimulates significant 
production of IL-1, IL-1, IL-6, TNF, MIP1, G-CSF, and 
Figure 4.  The action of Tim3-Ig is inde-
pendent of iNOS and IFN- and is medi-
ated by a soluble factor. (A) WT, iNOS/, 
and IFN-R/ macrophages (MP) were in-
fected with H37Rv and CFUs determined on 
day 1 (d1) and day 4 (d4). On day 1, Tim3tg 
splenocytes (Tg Spl), 10 µg/ml Tim3-Ig, or  
10 µg/ml HuIgG (control) were added to the 
macrophages. Data are representative of three 
independent experiments. Bars indicate mean ± 
SEM from three replicate cultures. (B) Con-
ditioned media from Mtb-infected macro-
phages cultured alone for 24 h (No Tx) or 
treated with 10 µg/ml Tim3-Ig or HuIgG for  
24 h were added to infected macrophages on day 1 after infection. CFUs were enumerated 3 d later on day 4 after infection. Dotted line represents the 
initial inoculums determined on day 1 (4.6 × 104). Data are from one experiment with three replicate cultures per condition. Error bars indicate mean ± SEM 
from three replicate cultures. *, P < 0.05; **, P < 0.01; ***, P < 0.001, one-way ANOVA compared with day 4 macrophages alone in A and to No Tx in B.2348 Tim3–Gal9 interaction in tuberculosis | Jayaraman et al.
dehydrogenase (LDH) release assay (unpublished data). How-
ever, the actual multiplicity of infection (MOI) of the infected 
macrophages is very low, and only <1% of cells are infected. 
The low frequency of infected cells could make it difficult to 
sensitively detect cell death. To address this issue, overnight 
infections were performed instead of our standard 2 h infec-
tion, and the MOI was varied. Necrosis was measured after   
3 d, and cells were treated with staurosporine served as a con-
trol. No increase in LDH release was caused by Tim3-Ig treat-
ment, although the overall necrosis paralleled the increase in 
MOI (Fig. 6 A). Because apoptosis is also associated with con-
trol of intracellular Mtb replication, we determined whether 
Tim3-Ig treatment induced apoptosis. An ELISA was used to 
measure intracellular and extracellular DNA–histone com-
plexes, which is indicative of apoptosis and necrosis, respec-
tively (Divangahi et al., 2009). Again, Tim3-Ig treatment did 
not increase the relative amount of necrosis or apoptosis ob-
served in Mtb-infected macrophages (Fig. 6 B). Thus, Tim-Ig 
treatment does not induce pyroptosis and necrosis does not 
correlate with Tim3–Gal9–induced antimicrobial activity.
IL-1 is required for the antimicrobial activity  
induced by Tim3
Our finding that bacterial killing can be transferred by a   
caspase-1–dependent secreted factor raised the possibility that 
IL-1 is the critical mediator induced by Tim3–Gal9 binding 
on Mtb-infected macrophages. Neutralizing antibody to IL-1 
was added to Tim3-Ig–treated Mtb-infected peritoneal mac-
rophages. Treatment with anti-IL-1, but not an isotype con-
trol abrogated the antimicrobial effect of Tim3-Ig (Fig. 7 A). 
To show that this pathway is relevant for lung macrophages, 
alveolar macrophages were obtained from uninfected mice 
and infected in vitro. Treatment with Tim3-Ig led to control 
of Mtb growth and blockade of IL-1 abrogated the induction 
of antimicrobial activity of Tim3-Ig (Fig. 7 B). IL-1 treat-
ment of Mtb-infected alveolar macrophages was sufficient to 
control growth of intracellular Mtb (Fig. 7 B). These results 
indicate that exogenously added IL-1 recapitulates the effects 
of Tim3-Ig, indicating that IL-1 is both necessary and suffi-
cient to activate the mycobactericidal activity of infected 
macrophages. Tim3-Ig treatment did not modulate expression 
of IL-1RA or IL-1R (CD121, IL-1R; Fig. S7). The action of 
IL-1 is mediated by binding to its cognate receptor, IL-1R, 
which forms a proximal signaling complex with MyD88 
through TIR domains (Weber et al., 2010). We therefore hy-
pothesized that the antimicrobial action of IL-1 is mediated 
through its receptor. To confirm the specificity of its action, 
we compared the protective efficacy of Tim3-Ig using in-
fected WT and IL-1R/ macrophages. As a control, we show 
that WT  naive  splenocytes  suppress  intracellular  bacterial 
Figure 5.  Tim3–Gal9 interaction induces caspase-1–dependent 
secretion of IL-1 and Mtb killing. (A) Mtb-infected WT C57BL/6J 
macrophages (MP) or Caspase-1/ macrophages were cultured alone or 
with 10 µg/ml of Tim3-Ig fusion protein or HuIgG (control). 24 h later, 
culture supernatants from triplicate wells were assayed for IL-1. Open 
bars indicate uninfected macrophages, and closed bars indicate Mtb-
infected macrophages. Data are representative of seven independent 
experiments. Error bars indicate mean ± SEM from three replicate cul-
tures. ***, P < 0.001, one-way ANOVA compared with untreated macro-
phages alone. (B) WT C57BL/6J or caspase-1/ macrophages were 
infected with H37Rv in parallel. On day 1, Tim3Tg CD4+ T cells, Tim3-Ig, or 
HuIgG (control) were added to the macrophages. CFUs were determined 
on day 1 and day 4 (d4) after infection. Data are representative of three 
independent experiments. Bars indicate mean ± SEM from three replicate 
cultures. (C) WT C57BL/6J macrophages infected with H37Rv was co-
cultured with Tim3-Ig in the presence or absence of Z-YVAD-Fmk  
(caspase-1 inhibitor) titrated fivefold. CFUs were determined on day 0, 2 h 
after Mtb infection, and on day 4. Z-FA-Fmk, negative control peptide for 
caspase-1 inhibitor. HuIgG, control for Tim3-Ig. Macrophages were also 
treated with 10 µM caspase-1 inhibitor and 10 µM negative peptide control 
in the absence of Tim3-Ig. *, P < 0.05; **, P < 0.01; ***, P < 0.001, one-way 
ANOVA compared with day 4 macrophages alone. Data are representative 
of three to four independent experiments. Error bars indicate mean ± SEM 
from three replicate cultures.
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Tim3-Ig treatment of Mtb-infected macrophages and may 
enhance  control  of  intracellular  Mtb  replication  (Fig.  S5). 
However, our finding that neutralizing antibodies to IL-1 
completely  inhibit  Tim3-Ig–mediated  suppression  of  Mtb 
growth suggests that IL-1 activates infected macrophages 
and  recruits  additional  antimicrobial  effector  functions.   
IL-1 signaling is both necessary and sufficient to restrict 
bacterial replication.
The ability of caspase-1 inhibitors and neutralizing anti-
bodies specific for IL-1 to abrogate intracellular control of 
Mtb shows that the autocrine action of IL-1 is required to 
mediate the antimicrobial effects of Tim3–Gal9 signaling. Active 
IL-1 secretion depends on caspase-1 activity, which in turn 
requires the assembly and activation of the inflammasome, an 
innate response to pathogenic bacteria (Mariathasan and   
Monack, 2007; Yu and Finlay, 2008). Under some conditions, 
Mtb and Mycobacterium marinum activate the Nalp3 inflamma-
some leading to caspase-1 activation and secretion of IL-1 
(Koo et al., 2008). High MOI infection with virulent Mtb, 
which favors necrosis, also stimulates IL-1 production. Under 
the conditions used for our studies (low MOI, <1% of cells 
infected), IL-1 secretion by infected macrophages was not 
detected. Only when infected macrophages were treated with 
Tim3-Ig was IL-1 secreted. Conversely, mycobacterial spe-
cies produce caspase-1 inhibitors, such as the zinc metallopro-
tease 1, which prevents phagosome maturation (Master et al., 
2008). We speculate that Tim3–Gal9 interaction may over-
come zinc metalloprotease 1 inhibition of caspase-1 activity 
by increasing the amount of active caspase-1, which would 
promote IL-1 secretion and activate bactericidal pathways.
IL-1 is an essential cytokine for host resistance to Mtb. 
Both IL-1R/ and IL-1/ mice rapidly succumb after 
infection with virulent Mtb infection (Fremond et al., 2007; 
growth in both WT and IL-1R/ macrophages. In contrast, 
Tim3-Ig  treatment  suppresses  Mtb  growth  in WT  macro-
phages but not in IL-1R/ macrophages (Fig. 7 C). These 
results show that autocrine IL-1 signaling via the IL-1R is 
an important mechanism by which Tim3–Gal9 interaction 
induces antimicrobial activity in infected macrophages.
DISCUSSION
Since its discovery in 2001, much has been learned about the 
role of Tim3 as a negative regulator of effector TH1 immu-
nity in peripheral tolerance and during autoimmune disease 
(Monney et al., 2002; Sabatos et al., 2003; Sánchez-Fueyo   
et al., 2003; Zhu et al., 2005; Koguchi et al., 2006). Consis-
tent with its capacity to inhibit T cell function, recent evi-
dence indicates that Tim3 is a marker of dysfunctional T cells 
in patients with chronic HIV and HCV infection (Jones   
et  al.,  2008;  Golden-Mason  et  al.,  2009).  Blockade  with 
Tim3-Ig or anti-Tim3 mAb can augment immunity against 
these pathogens, indicating that Tim3 signaling may regulate 
T cell death or exhaustion (Jones et al., 2008; Golden-Mason 
et al., 2009). Although the consequences of Tim3 signaling 
on T cells have been the focus of numerous studies, whether 
there is a reciprocal signal transmitted to the participating 
Gal9-expressing APC is unknown. Here, we provide the first 
data that Tim3–Gal9 binding activates the Gal9+ APC. Using 
in vitro assays and in vivo models with the human pathogen 
Mtb, we show that a positive activating signal is transduced in 
a Gal9-dependent manner into infected macrophages after its 
interaction with Tim3. Tim3–Gal9 binding stimulates bacte-
ricidal activity in infected macrophages that is independent of 
IFN- and iNOS. Instead, the innate pathways activated by 
Tim3–Gal9 binding lead to caspase-1-dependent secretion of 
IL-1. Other soluble factors such as TNF are secreted after 
Figure 6.  Tim3–Gal9 interaction does not 
induce cell death in Tim3-Ig–treated mac-
rophages. (A) WT macrophages were infected 
overnight at MOIs of 5, 10, 20, and 50.  
Uninfected and Mtb-infected macrophages 
were either cultured alone or with 10 µg/ml of 
Tim3-Ig fusion protein or human IgG (control). 
1 µM staurosporine was added 24 h before LDH  
assay to induce necrosis and serve as positive 
control. 3 d after infection, culture super-
natants were assayed for LDH release.  
(B) Enzyme-linked immunosorbent assay of 
apoptosis (right) and necrosis (left) 3 d after 
infection of WT macrophages cultured either 
alone or treated with 10 µg/ml of Tim3-Ig fu-
sion protein or human IgG (control). Open bars 
indicate uninfected macrophages and closed 
bars indicate Mtb-infected macrophages. 1 µM 
staurosporine was either added 24 h before to 
induce necrosis or 3 h before assay to induce 
apoptosis. Data in A is representative of three 
independent experiments. Data in B is repre-
sentative of two independent experiments.2350 Tim3–Gal9 interaction in tuberculosis | Jayaraman et al.
of IL-1 in host immunity to tuberculosis. Although IL-1 
production is generally acknowledged to require both Toll-
like receptor signaling and caspase-1 activity, IL-1 function 
early during the host response to Mtb infection is indepen-
dent of these two factors. IL-1 has several activities that could 
inhibit mycobacterial replication. IL-1 induces COX-2, PGE2, 
and EP4 in a variety of cell types (Takii et al., 1992; Tetsuka   
et al., 1994; Guan et al., 1997; Watanabe et al., 2009). Although 
it is unknown whether this occurs in Mtb-infected macro-
phages treated with Tim3-Ig, we have previously shown that 
these proinflammatory mediators play a key role in inhibiting 
necrosis of Mtb-infected macrophages by preventing mito-
chondrial inner membrane instability and repairing plasma 
membrane damage (Divangahi et al., 2009). Therefore, IL-1 
secretion secondary to Tim3–Gal9 interaction might induce 
the prostanoid production and promote macrophage apopto-
sis instead of necrosis (Divangahi et al., 2009). Although   
further work is required to delineate the signaling pathways 
that culminate in the control of intracellular Mtb, our current 
studies provide the first evidence that IL-1 directly stimu-
lates bactericidal activity in Mtb-infected macrophages.
Tim3 is an important negative regulatory molecule for 
TH1 and CD8+ T cells. It functions to maintain tolerance and 
to terminate effector T cell responses by inducing apoptosis 
(Kashio et al., 2003; Sabatos et al., 2003; Sánchez-Fueyo et al., 
2003; Zhu et al., 2005). In the case of acute infection, Tim3 
signaling may be an important mechanism that limits tissue 
damage  and  immunopathology  from  an  uncontrolled  im-
mune response. On the other hand, during chronic infection, 
Tim3 signaling could be detrimental if it leads to suboptimal 
immunity because of premature clonal contraction or T cell 
exhaustion (Jones et al., 2008; Golden-Mason et al., 2009). 
However, the effect of Tim3–Gal9 signaling on antimicrobial 
immunity in vivo is likely to be a balance between its poten-
tial negative effects on T cells and its ability to stimulate bac-
tericidal pathways in APCs to counter intracellular pathogens. 
This leads us to propose that Tim3, which predominantly ap-
pears on effector T cells, has evolved to inhibit intracellular 
pathogens by activating innate cells via Gal9, which, in turn, 
when expressed at high levels dampens effector T cells and 
prevents immunopathology. By providing a feedback-signaling 
loop involving cytokines including IFN- and IL-1 to 
up-regulate Gal9, Tim3 could play a central role in a bidirec-
tional regulatory circuit that activates APCs to inhibit intra-
cellular pathogens and the activated APCs in turn inhibit/ 
terminate Tim3+ effector T cells (Fig. S8). IFN- and IL-1 
may participate at different stages of infection to regulate the 
production of Gal9. Understanding how Gal9, which is a   
secreted molecule but also decorated on cell surface, signals 
and leads to macrophage activation is an important question. 
There is precedence for secreted proteins assembling on the 
cell surface with transmembrane proteins to form a signal 
transduction complex (Kirschning et al., 1998; Yang et al., 
1998; Means et al., 1999). We propose that Tim3 and Gal9 
form a complex that includes other membrane proteins and 
facilitates the activation of macrophages. There is likely to be 
Juffermans et al., 2000; Sugawara et al., 2001; Yamada et al., 
2000). Furthermore, the discrepancy between the substantial 
susceptibility of MyD88/ mice and the absent or modest 
phenotype of other Toll-like receptor knockout strains sug-
gests that the critical role of MyD88 during Mtb infection is 
a manifestation of its requirement for IL-1R signaling (Fremond 
et al., 2007; Mayer-Barber et al., 2010). Although the greater 
susceptibility of caspase-1/ mice than WT mice suggests a 
role for caspase-1 in the control of Mtb, Mayer-Barber et al. 
(2010) show that IL-1/ mice are significantly more sus-
ceptible than caspase-1/ mice. This recent data suggest that 
alternate pathways exist that lead to the secretion and function 
Figure 7.  IL-1 is necessary and sufficient to mediate Mtb killing. 
Mtb-infected WT peritoneal (A) or alveolar (B) macrophages (MP) were 
cultured either alone or in the presence of 10 µg/ml Tim3-Ig fusion pro-
tein with and without 25 µg/ml anti–IL-1 neutralizing antibody or iso-
type control (IC). No Tx, treatment with Tim3-Ig alone in the absence of 
neutralizing antibodies. Data in A is representative of 5–11 independent 
experiments. Data in B is from one experiment. Bars indicate mean ± SEM 
from three to six replicate cultures. (C) WT C57BL/6J or IL-1R/ macro-
phages were infected with H37Rv in parallel. On day 1 (d1), WT spleno-
cytes, Tim3-Ig, or HuIgG (control) were added to the macrophages. CFUs 
were determined on d1 and day 4 (d4) after infection. Representative data 
from three independent experiments are shown. CFUs were determined 
on day 1 and day 4 after infection. Data are from one experiment. Error 
bars indicate mean ± SEM from three to six replicate cultures. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001, one-way ANOVA compared with day 4 macro-
phages alone.JEM VOL. 207, October 25, 2010 
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mented with 2% human serum/10% FBS/0.05% Tween 80, washed twice 
with complete medium without antibiotics. Bacteria were passed through a 
5-µm syringe filter (Millipore), counted in a Petroff-Hausser chamber, and 
added to macrophages at the MOI indicated. The length of infection was 2 h 
for all experiments. Infected macrophages were cultured overnight before 
the addition of splenocytes, purified cell subsets, or other conditions. At days 
1 and 4 after infection, cells were lysed with 1% Triton X-100 for 5 min and 
mycobacteria enumerated by plating serial dilutions of cell lysates on Mid-
dlebrook 7H10 agar plates and culture at 37°C. Colonies were counted after 
21 d. WT and Tim3tg splenocytes were aseptically prepared, and CD4+  
T cells were enriched by magnetic cell sorting using microbeads. CD4+ 
TIM3+ T cells from Tim3tg mice were sorted and cell purity was >90% as 
determined by flow cytometry. 2.5 × 106 splenocytes or T cells/well were 
added to Mtb-infected macrophages. In all the culture conditions, CFU was 
enumerated at day 1 (unless otherwise indicated) in untreated infected mac-
rophages to determine initial inoculum and at day 4 after infection to deter-
mine growth of intracellular Mtb in untreated infected macrophages and 
relative suppression/killing mediated by various treatments. The “experi-
mental” MOI is calculated by dividing the CFU recovered on day 1 by the 
number of macrophages per well. For example, recovery of 2,000 CFU in   
a well containing 500,000 macrophages indicates an experimental MOI of 
0.004 (Fig. 3 A).
Alveolar macrophage isolation and infection. Alveolar macrophages 
were isolated by bronchoalveolar lavage. Mice were sacrificed by CO2 inha-
lation. Lungs were lavaged with 1 ml sterile saline each time through an in-
tratracheal catheter, and a total of 10 ml saline was instilled and recovered 
from each mouse. The lavage fluid was centrifuged at 300 g for 10 min to 
pellet cells, and 95–98% of cells recovered were macrophages (alveolar mac-
rophages).The pelleted cells were resuspended and cultured in a 96-well   
culture plate at 37°C with 5% CO2 at a concentration of 5 × 104 cells per 
well in 200 µl RPMI 1640 medium (Sigma-Aldrich) supplemented with 
10% FBS, 1 mM pyruvate, 1% nonessential amino acids, 1% minimal essential 
amino acids, 2 mM l-glutamine, 7 mM NaOH, and 20 mM Hepes. After 24 h 
of incubation, nonadherent cells were washed off with PBS, and the medium 
was refreshed. Alveolar macrophages were infected with H37Rv according 
to methods mentioned in the previous section for peritoneal macrophages.
Tim3-Ig fusion protein treatment and Gal9, iNOS, caspase, IL-1 
inhibition studies. Tim3-Ig constructed as human IgG1 Fc tail fusion pro-
tein, is available as full-length or soluble Tim3-Ig based on the domains in-
cluded in the fusion protein construct (Sabatos et al., 2003; Sánchez-Fueyo   
et al., 2003). Fusion proteins contained <0.1 EU/µg of LPS (Chimerigen 
Laboratories). In all in vitro infections, both flTim3-Ig and sTim3-Ig were 
used and data obtained were identical. However, for simplicity, data from   
either fusion protein is included in the figures. flTim3-Ig, sTim3-Ig, and 
HuIgG (control) were added to Mtb-infected macrophages at the concentra-
tions indicated in the figure legends. After a 20-min incubation, goat F(ab’)2 
anti–human Ig at a final concentration of 2.5 µg/ml was added to cross-link 
the fusion proteins or HuIgG. Tim3–Gal9 interaction was inhibited using 
differing final concentrations of -lactose (12.5, 25, 50, and 100 mM) that 
was added to the culture media before 10 µg/ml Tim3-Ig treatment. To eval-
uate  the  role  of  iNOS  in Tim3-mediated  Mtb  control,  iNOS  inhibitors   
L-NMMA (2 mM) and L-NIL (0.5 mM) were added to Mtb-infected macro-
phages 1 h before addition of WT and Tim3tg splenocytes. To determine 
whether caspase-1 was involved in Tim3-Ig–mediated control, caspase-1 in-
hibitor (Z-YVAD-Fmk; 0.08, 0.4, 2, and 10 µM final concentrations) was 
added to the culture media 20 min before Tim3-Ig treatment. Negative con-
trol peptide (Z-FA-Fmk) was added at 10 µM final concentration. As a con-
trol for cytoxicity, we treated macrophages with caspase-1 inhibitor and the 
negative control peptide at the highest concentration (10 µM) tested in the 
absence of Tim3-Ig. Our ability to recover similar levels of intracellular my-
cobacteria in caspase-1/negative peptide inhibitor–treated macrophages and 
untreated macrophages indicated that there was minimal cytotoxicity associ-
ated with these inhibitors at the concentrations used. To test control of Mtb 
strict regulation in the expression of Gal9 and a Gal9 dose-
dependent regulation of T cell and macrophage activation that 
in turn determine their cellular fates.
In summary, our work provides the first evidence that 
during T cell–APC interaction, Gal9 signaling leads to activa-
tion of macrophages. We propose that although Tim3–Gal9 
signaling regulates effector T cell expansion and tolerance in-
duction, and prevents prolonged inflammation in target tissues 
under certain conditions, it may have primarily evolved to acti-
vate the innate immune system to control intracellular patho-
gens. How these two potentially opposing functions mediated 
by Tim3 and Gal9 are balanced in vivo during chronic infec-
tion requires further elucidation. Tim3 and Gal9 thus repre-
sent novel cell surface targets to modulate antimicrobial 
immunity and control infection in vivo.
MATERIALS AND METHODS
Materials. The following reagents were used in this study: anti-CD3 (145-
2C11; BD), anti-CD4 (GK1.5; BD), anti-CD8 (53–6.7; BD), rat anti–mouse 
CD16/CD32  (Fc-Block;  BD),  anti-Tim3  (5D12;  V.K.  Kuchroo),  goat 
F(ab’)2  anti–human  Ig  (2012–01;  SouthernBiotech),  CD11b  microbeads 
(Miltenyi Biotec), CD4 microbeads (Miltenyi Biotec), human IgG1 (I5154; 
Sigma-Aldrich), human serum (Gemini Bioproducts), -lactose (L-3625; 
Sigma-Aldrich), NG-monomethyl-l-arginine (L-NMMA; 475886; Calbio-
chem), L-N6-(1-Iminoethyl)lysine dihydrochloride (L-NIL; 482100; Cal-
biochem), caspase-1 inhibitor VI (Z-YVAD-Fmk; 218746; Calbiochem), 
caspase inhibitor negative control (Z-FA-Fmk; 342000; Calbiochem), recom-
binant mouse IL-1 (rIL-1; R&D Systems), anti–IL-1 (B122; eBioscience), 
Armenian hamster IgG (eBio299Arm; eBioscience), proteome profiler mouse 
cytokine  array  (ARY006;  R&D  Systems),  cytotoxicity  detection  kitplus 
(LDH; 04744926001; Roche), Cell Death Detection ELISAPLUS (11 920685 
001; Roche), QuantiTect reverse transcription kit (QIAGEN), TRIzol (Invi-
trogen), TRIzol plus RNA purification system (Invitrogen), Brilliant SYBR 
Green QPCR master mix (Stratagene), Remel 7H10 M.tb plates (R01610; 
Thermo Fisher Scientific), full-length Tim3-Ig fusion protein (flTim3-Ig; 
V.K. Kuchroo), soluble Tim3-Ig fusion protein (sTim3-Ig; V. Kuchroo), 
and IL-1 ELISA antibody pairs (14–7012; 13–7112; eBioscience).
Mice. 6–10-wk-old C57BL/6J or Rag1/ or IL-1R/ were purchased from 
Jackson ImmunoResearch Laboratories; Galectin-9/ was obtained from 
V. Kuchroo; Tim3tg and Tim3/ mice (obtained from V. Kuchroo) were bred 
locally; Caspase-1/ mice were obtained from M. Starnbach (Harvard Medical 
School, Boston, MA). All procedures were approved by the Institutional Animal 
Care and Use Committee of the Dana Farber Cancer Research Institute.
Bacteria, cells, and culture. Virulent Mtb (H37Rv) was grown to mid-
log phase in Middlebrook 7H9 broth (BD) with BBL Middlebrook OADC 
Enrichment (BD) and 0.05% Tween 80 (Difco). Aggregation was prevented 
by sonication for 10 s. CD11b+ peritoneal macrophages were harvested after 
being elicited with 3% thioglycollate followed by CD11b+ selection using 
MACS columns. Purified cells were >95% F4/80+ CD11b+, as determined 
by flow cytometry. Macrophages (0.5 × 106 cells per well) were seeded in a 
24-well culture plate in complete RPMI 1640 medium (Invitrogen Life 
Technologies) supplemented with 10% FBS (HyClone), 1 mM pyruvate, 1% 
nonessential amino acids, 1% minimal essential amino acids, 2 mM l-glutamine, 
7 mM NaOH, and 20 mM Hepes (all from Invitrogen). Cells were allowed 
to adhere for 2–24 h before in vitro infection with Mtb.
In vitro infections and co-cultures. Peritoneal macrophages were infected 
with H37Rv at a MOI of 10 as previously described (Sada-Ovalle et al., 2008). 
In brief, Mtb were opsonized for 5 min using RPMI 1640 medium supple-2352 Tim3–Gal9 interaction in tuberculosis | Jayaraman et al.
was calculated according to the formula: (LDH activitytest sample, SN  LDH 
activityuntreated uninfected macrophage, SN)/(Maximal releasable LDHSN+lys  LDH 
activityuntreated uninfected macrophage, SN), where SN is the amount in the supernatant 
and Lys is the amount in the lysates. In some experiments, apoptosis and 
necrosis were measured by enzyme-linked immunosorbent assay cell (Cell 
Death Detection ELISAPLUS; Roche) for quantification of cytoplasmic 
(apoptosis) and extracellular (necrosis) histone-associated DNA fragments 
according to the specifications of the manufacturer. The relative amount of 
necrosis or apoptosis was calculated as a ratio of the absorbance of infected 
macrophages to that of uninfected control macrophages.
Aerosol infection of mice. All in vivo infections were performed using 
virulent H37Rv (Erdman strain) by the aerosol route with a nose-only ex-
posure  unit  (Intox  Products)  that  delivers  100–200  CFU  per  mouse 
(Woodworth et al., 2008). At different times after infection, mice were eu-
thanized by carbon dioxide inhalation and lungs and spleens were aseptically 
removed.  Organs  were  individually  homogenized  in  0.9%  NaCl/0.02% 
Tween 80 with MiniBead Beater 8 (BioSpec Products) and viable bacteria 
were enumerated by plating 10-fold serial dilutions of organ homogenates 
onto 7H10 agar plates. Colonies were counted after 21 d.
In vivo treatment with Tim3-Ig. WT and Rag/ mice were treated 
with flTim3-Ig, sTim3-Ig, or HuIgG (control). The antibodies (0.5 mg 
each) were administered intraperitoneally 1 d after aerosol infection, fol-
lowed by administration of 0.1 mg of antibody 5, 8, and 12 d after infection. 
2 and 3 wk after infection, mice were euthanized and CFU was enumerated 
in lungs and spleens.
Adoptive transfer model of infection. Elicited peritoneal macrophages 
from WT and Gal9/ mice were isolated and infected in vitro with H37Rv 
as previously described. Suspended macrophages were infected for 1 h in vitro 
at a MOI of 10:1 of H37Rv. Free bacteria were then removed by six washes 
with PBS, each followed by centrifugation for 10 min at 200 g and 4°C. 
Cells were resuspended in PBS at a density of 0.5E6 cells per 100 µL, and 
then transferred by the intravenous route into naive Tim3tg mice. At 7 and 
14 d after adoptive transfer, mice were euthanized and CFU was enumerated 
in lungs and spleens.
Flow cytometry. Pulmonary and splenic cells from infected and uninfected 
WT C57BL/6J mice were stained for 20 min at 4°C with 25 µg/ml of anti–
CD3-FITC, anti–CD4-PE, anti–CD8-PerCP, and anti–Tim3-APC antibodies. 
To inhibit nonspecific staining, murine FC receptors were blocked with   
25 µg/ml of Fc-block for 15 min at 4°C before staining with fluorochrome-
conjugated antibodies and appropriate isotype controls. Splenic T cells from 
uninfected Tim3tg mice were stained for CD3/CD4/CD8/Tim3 in a simi-
lar manner to determine Tim3+ T cells in Tim3tg mice. Data were collected 
using a FACSCanto (BD) and analyzed with FlowJo (Tree Star, Inc.).
Statistical analysis. The data from the in vivo Tim3-Ig treatment experi-
ments were analyzed by the nonparametric Kruskal-Wallis test (95% confi-
dence interval) with Dunnett’s post-test comparing. A one-way ANOVA 
was used to analyze the in vitro macrophage infections, and Dunnett’s post-
test was used to compare the day 4 control condition (infected and/or un-
treated macrophages) to the other groups. Analysis was performed using 
Prism 5.0 software (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows intracellular Gal9 expres-
sion in distinct myeloid subsets in lungs of Mtb-infected mice, induction 
of intracellular Gal9 in peritoneal macrophages after LPS stimulation, and 
induction of Gal9 transcripts after treatment with IFN- and Mtb infec-
tion. Fig. S2 shows representative FACS plots of greater Tim3 expression 
in T cells in Tim3tg mice compared with WT mice. Fig. S3 shows that 
Tim3 expression by splenocytes is crucial for Mtb control in infected macro-
phages. Fig. S4 shows that the antimicrobial action of Tim3-mediated 
Mtb control is independent of iNOS. Fig. S5 shows that a novel activa-
tion state is induced after Tim3-Ig treatment of Mtb-infected macrophages 
by IL-1, rIL-1 at a final concentration of 10 ng/ml was added directly to 
media containing infected macrophages. To determine whether IL-1 was 
required for Tim3-Ig–mediated Mtb killing, anti–IL-1 (25 µg/ml; final concen-
tration) was added separately or in combination with anti–IL-1 (25 µg/ml; 
final concentration) to infected macrophages along with 10 µg/ml Tim3-Ig. 
To account for any cells dying after Tim3-Ig treatment and releasing myco-
bacteria into cell culture supernatant, leading to underestimation of the total 
amount of Mtb in infected macrophages, we measured CFU the following: 
(a) removal of supernatant, lysis of macrophages in 1% Triton X-100, and 
plating the supernatant and the macrophage lysate; or (b) lysing macrophages 
without the removal of cell culture supernatant by adding 10% Triton X-100 
at 1/10th the cell culture volume. Under the standard in vitro infection con-
ditions, we detected <10% of the total CFU in the cell culture supernatant. 
The CFU present in the supernatant was not statistically significant between 
macrophages treated with media, Tim3-Ig, or HuIgG.
Cytokine and chemokine detection. Culture supernatants from unin-
fected and infected macrophages after Tim3-Ig treatment were filtered through 
0.2 µM filter to remove any bacteria. Supernatants were assayed for cyto-
kines and chemokines by either a sandwich ELISA or by mouse proteome 
cytokine profiler. ELISA was done in accordance with the manufacturer’s 
instructions, and absorbance was recorded at 405 nm on SoftMax Pro ELISA 
analysis software (Molecular Devices). IL-1 in culture supernatants was 
quantified by comparison with the appropriate recombinant standard (pur-
chased  from  eBioscience).  For  the  proteomic  blots,  culture  supernatants 
from uninfected and infected macrophages treated with and without Tim3-Ig 
were mixed with a cocktail of biotinylated detection antibodies for various 
chemokines/cytokines provided with the kit and used to probe nitrocellu-
lose membranes with spotted capture antibodies according to manufacturer’s 
instructions. Any cytokine/detection antibody complex present is bound to 
its cognate immobilized capture antibody on the membrane. Streptavidin-
HRP detection agents were subsequently used to develop the blot with the 
intensity of the spot in direct proportion to the amount of cytokine bound.
Real-time  reverse  transcription-PCR.  Total  RNA  from  equivalent 
macrophage numbers (typically 1–2 × 106 macrophages, pooled from 2–4   
replicate wells) was isolated with Trizol plus RNA purification system, and 
200–500 ng RNA was transcribed into cDNA using random hexamers and 
QuantiTect (QIAGEN) reverse transcription kit according to the manufac-
turer’s instructions. The cDNA was denatured for 10 min at 95°C. Specific   
DNA fragments were amplified using Brilliant SYBR Green QPCR Master   
Mix and Mx3000p qPCR Stratagene cycler for 40 cycles of 95°C for 15 s,   
56°C for 60 s, and 72°C for 30 s. The oligonucleotide primers used were as 
follows: GAPDH, 5-AGGTCGGTGTGAACGGATTTG-3 (forward) and   
5-TGTAGACCATGTAGTTGAGGTCA-3 (reverse); IL-1, 5-GCAACT-
GTTCCTGAACTCAACT-3  (forward)  and  5-ATCTTTTGGGGTCC-
GTCAACT-3 (reverse); IL-18, 5-GACTCTTGCGTCAACTTCAAGG-3 
(forward) and 5-CAGGCTGTCTTTTGTCAACGA-3 (reverse); galec-
tin-9, 5-GTTGTCCGAAACACTCAGAT-3 (forward) and 5-ATAT-
GATCCACACCGAGAAG-3 (reverse). Threshold cycle numbers (Ct) 
were determined and transformed using Ct method as described by the 
manufacturer, using GAPDH as the calibrator. Expression of Gal9, IL-18, 
and IL-1 was calculated as fold increase over uninfected/untreated macro-
phages alone.
In vitro assays of necrosis and apoptosis. Necrosis/pyroptosis in mac-
rophages was evaluated through the release of the intracellular enzyme LDH 
in cell culture supernatants. The in vitro infections performed were done at 
a low (actual) MOI, resulting in 1–2% of cells being infected. Under these 
standard in vitro infection conditions, we did not detect LDH release. To im-
prove the sensitivity of the LDH assay we sought to increase the frequency 
of infected cells by infecting the macrophages overnight as opposed to 2 h. 
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